STAR vs THEMISMED: Stock Comparison

Strides Pharma Science Limited vs Themis Medicare Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Strides Pharma Science Limited is the larger company by market capitalisation. Strides Pharma Science Limited shows a lower P/E, a higher ROE and faster revenue growth, while Themis Medicare Limited shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Strides Pharma Science Limited and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, STAR is more favourable on 10 of 13 scored metrics and THEMISMED on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
STAR is the larger company
₹9,626 Cr vs ₹972 Cr
P/E Ratio
STAR has a lower P/E
17.16x vs 883.33x
P/B Ratio
THEMISMED has a lower P/B
2.45x vs 3.07x
EPS
STAR has higher earnings per share
₹60.31 vs ₹0.12
Dividend Yield
THEMISMED has a higher dividend yield
0.43% vs 0.37%
Revenue Growth (TTM YoY)
STAR has faster revenue growth
11.2% vs 6.7%
EPS Growth (TTM YoY)
STAR has faster EPS growth
54.4% vs 0%
Qtr Sales Growth
STAR has stronger quarterly sales growth
11.2% vs 6.74%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSTARTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSTARTHEMISMED
Live Price₹1,041.7₹105.78
Day Change-0.12%-1.99%
Volume89,68534,271
52-Week High₹1,231₹148
52-Week Low₹768.65₹64.95
Distance from 52W High-15.38%-28.53%

Valuation

MetricSTARTHEMISMED
Market Cap₹9,626 Cr₹972 Cr
P/E Ratio17.16x883.33x
P/B Ratio3.07x2.45x
EPS₹60.31₹0.12
Book Value₹337.09₹43.06
Dividend Yield0.37%0.43%

Growth

MetricSTARTHEMISMED
Revenue Growth (TTM YoY)11.2%6.7%
EPS Growth (TTM YoY)54.4%0%
Qtr Sales Growth11.2%6.74%
Qtr Profit Growth28.1%192%

Profitability & Leverage

MetricSTARTHEMISMED
ROE20.4%0.29%
ROCE18.6%2.74%
Net Margin10.58%0.33%
Operating Margin19%-2.9%
Debt to Equity0.57x25.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSTARTHEMISMED
Promoter Holding27.91%57.5%
FII Holding28.39% 0.29 pp0.01% 0.1 pp
DII Holding15.41% 0.96 pp0.01%
Public Holding28.28% 0.67 pp32.87% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Strides Pharma Science Limited and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.